Pregled bibliografske jedinice broj: 68581
Klinički i terapijski pristup u uznapredovaloj parkinsonovoj bolesti
Klinički i terapijski pristup u uznapredovaloj parkinsonovoj bolesti // Neurologia Croatica / Barac, Boško ; Huber, Gerald (ur.).
Zagreb: The International Neuropsychiatric Symposia in Pula, 1999. str. 16-17 (pozvano predavanje, domaća recenzija, sažetak, ostalo)
CROSBI ID: 68581 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Klinički i terapijski pristup u uznapredovaloj parkinsonovoj bolesti
(Clinical and therapeutic aspects in complicated parkinsonism)
Autori
Relja, Maja
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
Neurologia Croatica
/ Barac, Boško ; Huber, Gerald - Zagreb : The International Neuropsychiatric Symposia in Pula, 1999, 16-17
Skup
39th International Neuropsychiatric Symposium
Mjesto i datum
Pula, Hrvatska, 02.06.1999. - 05.06.1999
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
Parkinsonnova bolest; diskinezije; levodopa; DA agonisti
(Parkinson's Disease; dyskinesias; levodopa; DA agonists)
Sažetak
Parkinsonism is a clinicaol syndrome characterized by specific motor deficit: tremor, rigidity, akinesia, and postural instability. At least two of these symptoms should be present to make diagnosis. In contrast to parkinsonism Parkinson's disease (PD) is a distinct clinical and pathological entity. It is the most common form of parkinsonism and it ios also on of the most cpommon causes of neurological disability, affecting 1 percent of the population over the age of 55.
Levodopa adjustment and adjunctive therapy with dopamine agonists form the major therapeutic medications strategies. Striatal DA concentration in advanced PD could also be enhanced by adding MAO-B inhibitors and COMT inhibitors (Parkinson Study Group, 1997). The weak glutamate NMDA receptor antagonist , amantadine, can be tried in patients failing levodopa therapy.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti